Key points are not available for this paper at this time.
For patients with metastatic colorectal cancer, second-line treatment with FOLFOX4 is superior to treatment with LVFU2 in terms of RR, TTP, and relief of TRS.
Rothenberg et al. (Thu,) studied this question.